

Alfredo L Nicosia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4660772/alfredo-l-nicosia-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

9,805
citations

51
h-index

96
g-index

146
ext. papers

10,942
ext. citations

10
avg. IF

5.15
L-index

#	Paper	IF	Citations
137	High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand.. <i>Cancers</i> , 2022 , 14,	6.6	3
136	A DNA/Ki67-Based Flow Cytometry Assay for Cell Cycle Analysis of Antigen-Specific CD8 T Cells in Vaccinated Mice. <i>Journal of Visualized Experiments</i> , 2021 ,	1.6	3
135	Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021 , 384, 541-549	59.2	25
134	MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	7
133	Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. <i>Scientific Reports</i> , 2020 , 10, 4307	4.9	13
132	A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability. <i>Cancer Research</i> , 2020 , 80, 3972-3982	10.1	17
131	A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008459	4.8	7
130	Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment. <i>Molecular Therapy - Oncolytics</i> , 2020 , 19, 253-264	6.4	8
129	Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Oncolytic Virus. <i>Cancers</i> , 2020 , 12,	6.6	13
128	New viral vectors for infectious diseases and cancer. <i>Seminars in Immunology</i> , 2020 , 50, 101430	10.7	17
127	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020 , 12,	6.6	4
126	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. <i>Npj Vaccines</i> , 2020 , 5, 94	9.5	5
125	Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. <i>Scientific Reports</i> , 2019 , 9, 13125	4.9	18
124	Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. <i>Nature Communications</i> , 2019 , 10, 2688	17.4	29
123	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. <i>Journal of Infection</i> , 2019 , 78, 382-392	18.9	24
122	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019 , 2019, 6051870		5
121	Antigen-specific CD8 T cells in cell cycle circulate in the blood after vaccination. <i>Scandinavian Journal of Immunology</i> , 2019 , 89, e12735	3.4	11

120	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018 , 8, 3390	4.9	30
119	A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. <i>MAbs</i> , 2018 , 10, 730-737	6.6	17
118	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. <i>MAbs</i> , 2018 , 10, 1060-1072	6.6	21
117	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. <i>Frontiers in Immunology</i> , 2018 , 9, 3175	8.4	19
116	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017 , 376, 928-938	59.2	179
115	Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication. <i>EBioMedicine</i> , 2017 , 18, 204-215	8.8	12
114	Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane. <i>Expert Review of Vaccines</i> , 2017 , 16, 1241-1252	5.2	33
113	Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix. <i>Journal of Immunotherapy</i> , 2017 , 40, 51-61	5	7
112	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017 , 8, 1551	8.4	16
111	Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017 , 2,	9.9	45
110	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. <i>Gut</i> , 2016 , 65, 2029-2034	19.2	16
109	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016 , 24, 1470-7	11.7	40
108	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016 , 374, 1635-46	59.2	232
107	Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. <i>Journal of General Virology</i> , 2016 , 97, 82-94	4.9	14
106	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016 , 4,	5.3	27
105	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016 , 11, e0167951	3.7	34
104	Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral. <i>Hepatology</i> , 2016 , 63, 1442-54	11.2	21
103	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. <i>Hepatology</i> , 2016 , 63, 1455-70	11.2	32

102	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015 , 7, 286re5	17.5	94
101	Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. <i>Science Translational Medicine</i> , 2015 , 7, 300ra126	17.5	93
100	Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. <i>Science Translational Medicine</i> , 2015 , 7, 300ra127	17.5	52
99	Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015 , 2, 15018	6.4	34
98	Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin. <i>Journal of Peptide Science</i> , 2015 , 21, 743-9	2.1	3
97	One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. <i>BioMed Research International</i> , 2015 , 2015, 703213	3	12
96	Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1076-86	7	100
95	Anti-CD81 but not anti-SR-BI blocks <i>Plasmodium falciparum</i> liver infection in a humanized mouse model. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1784-7	5.1	21
94	Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1129-46	15.9	67
93	Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. <i>Journal of Virology</i> , 2014 , 88, 5502-10	6.6	45
92	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. <i>Hepatology</i> , 2014 , 60, 1508-18	11.2	43
91	T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. <i>Hepatology</i> , 2014 , 60, 1531-40	11.2	51
90	Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. <i>Journal of Virology</i> , 2014 , 88, 12644-55	6.6	35
89	Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. <i>Molecular Therapy</i> , 2014 , 22, 2142-2154	11.7	51
88	Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. <i>Vaccine Journal</i> , 2014 , 21, 783-6		16
87	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. <i>Nature Medicine</i> , 2014 , 20, 1126-9	50.5	250
86	Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. <i>Molecular Therapy</i> , 2014 , 22, 1992-2003	11.7	39
85	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. <i>Virology</i> , 2014 , 458-459, 190-208	3.6	14

84	Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain. <i>PLoS ONE</i> , 2014 , 9, e100538	3.7	31
83	Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. <i>Molecular Therapy</i> , 2014 , 22, 1039-47	11.7	26
82	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014 , 6, 261ra153	17.5	233
81	Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. <i>Molecular Therapy</i> , 2014 , 22, 464-475	11.7	157
80	Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. <i>Journal of Virology</i> , 2014 , 88, 1725-39	6.6	37
79	Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. <i>Journal of Biological Chemistry</i> , 2014 , 289, 35015-28	5.4	12
78	A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. <i>PLoS ONE</i> , 2014 , 9, e115161	3.7	42
77	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013 , 4, 2836	17.4	223
76	Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. <i>Journal of Immunology</i> , 2013 , 190, 2720-35	5.3	74
75	Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. <i>Vaccine</i> , 2013 , 31, 5594-601	4.1	12
74	Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. <i>Expert Review of Vaccines</i> , 2013 , 12, 379-93	5.2	66
73	Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. <i>PLoS ONE</i> , 2013 , 8, e55435	3.7	40
72	Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. <i>PLoS ONE</i> , 2013 , 8, e57726	3.7	60
71	A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. <i>Hepatology</i> , 2012 , 55, 364-72	11.2	101
70	ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. <i>Molecular Therapy</i> , 2012 , 20, 2355-68	11.7	155
69	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. <i>Journal of Hepatology</i> , 2012 , 57, 17-23	13.4	64
68	Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. <i>Gastroenterology</i> , 2012 , 143, 1048-60.e4	13.3	58
67	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. <i>Science Translational Medicine</i> , 2012 , 4, 115ra1	17.5	310

66	Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. <i>Journal of Infectious Diseases</i> , 2012 , 205, 772-81	7	175
65	Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection. <i>Vaccine Journal</i> , 2012 , 19, 780-6		17
64	Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. <i>Science Translational Medicine</i> , 2012 , 4, 115ra2	17.5	210
63	Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. <i>Journal of Virology</i> , 2012 , 86, 4082-90	6.6	48
62	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. <i>Aids</i> , 2012 , 26, 275-84	3.5	33
61	Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. <i>PLoS ONE</i> , 2012 , 7, e31208	3.7	126
60	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+T-Cell Responses. <i>Infection and Immunity</i> , 2011 , 79, 2131-2131	3.7	78
59	Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. <i>Molecular Therapy</i> , 2011 , 19, 2269-76	11.7	134
58	Prime-boost vectored malaria vaccines: progress and prospects. <i>Hum Vaccin</i> , 2010 , 6, 78-83		171
57	Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. <i>Journal of Virology</i> , 2010 , 84, 34-43	6.6	121
56	Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. <i>Infection and Immunity</i> , 2010 , 78, 145-53	3.7	151
55	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. <i>Vaccine</i> , 2010 , 29, 256-65	4.1	58
54	Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. <i>Journal of Immunology</i> , 2010 , 185, 7583-95	5.3	73
53	Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. <i>European Journal of Immunology</i> , 2010 , 40, 1973-84	6.1	62
52	Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. <i>Journal of Oncology</i> , 2009 , 2009, 951917	4.5	20
51	A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. <i>Vaccine</i> , 2009 , 27, 1293-300	4.1	42
50	Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection. <i>Journal of Hepatology</i> , 2008 , 48, 216-28	13.4	7
49	Hepatitis C vaccine: supply and demand. <i>Lancet Infectious Diseases, The</i> , 2008 , 8, 379-86	25.5	61

48	The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. <i>Journal of Virology</i> , 2008 , 82, 9782-8	6.6	17
47	Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. <i>Journal of Gene Medicine</i> , 2008 , 10, 1048-54	3.5	7
46	Differential screening of phage-ab libraries by oligonucleotide microarray technology. <i>PLoS ONE</i> , 2008 , 3, e1508	3.7	6
45	High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. <i>Journal of Virology</i> , 2007 , 81, 8063-71	6.6	128
44	Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. <i>Journal of Immunology</i> , 2006 , 177, 7462-71	5.3	75
43	A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. <i>Journal of Virology</i> , 2006 , 80, 1688-99	6.6	69
42	A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. <i>Nature Medicine</i> , 2006 , 12, 190-7	50.5	250
41	Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. <i>European Journal of Immunology</i> , 2005 , 35, 2627-37	6.1	34
40	In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters. <i>Journal of Gene Medicine</i> , 2005 , 7, 1475-81	3.5	25
39	An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors. <i>Journal of Virology</i> , 2005 , 79, 6400-9	6.6	23
38	EXPOSURE TO HEPATITIS C VIRUS INDUCES CELLULAR IMMUNE RESPONSES WITHOUT DETECTABLE VIREMIA OR SEROCONVERSION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 44-49	3.2	40
37	Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 44-9	3.2	26
36	Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. <i>Hepatology</i> , 2003 , 38, 653-63	11.2	10
35	Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. <i>Journal of Biosciences</i> , 2003 , 28, 305-10	2.3	12
34	Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. <i>Journal of Virology</i> , 2003 , 77, 1856-67	6.6	140
33	Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. <i>Journal of Biological Chemistry</i> , 2003 , 278, 41624-30	5.4	456
32	The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. <i>EMBO Journal</i> , 2002 , 21, 5017-25	13	922
31	Biotin-tagged cDNA expression libraries displayed on lambda phage: a new tool for the selection of natural protein ligands. <i>Nucleic Acids Research</i> , 2002 , 30, e78	20.1	26

30	Searching for DNA-protein interactions by lambda phage display. <i>Journal of Molecular Biology</i> , 2002 , 322, 697-706	6.5	34
29	Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. <i>Hepatology</i> , 2001 , 33, 692-703	11.2	33
28	Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?. <i>Antiviral Research</i> , 2001 , 52, 153-9	10.8	42
27	Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus. <i>International Reviews of Immunology</i> , 2001 , 20, 289-300	4.6	12
26	Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. <i>Journal of Immunology</i> , 2001 , 167, 3878-86	5.3	28
25	Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. <i>Molecular Immunology</i> , 2001 , 38, 485-92	4.3	27
24	Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. <i>Journal of Virology</i> , 2000 , 74, 3642-9	6.6	187
23	A model for the hepatitis C virus envelope glycoprotein E2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2000 , 40, 355-66	4.2	177
22	High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment. <i>Virology</i> , 2000 , 269, 313-24	3.6	19
21	Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. <i>Journal of Virology</i> , 2000 , 74, 11598-607	6.6	112
20	Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. <i>Journal of Virology</i> , 2000 , 74, 5933-8	6.6	85
19	Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics. <i>Journal of Molecular Biology</i> , 2000 , 296, 497-508	6.5	71
18	Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. <i>Hepatology</i> , 1999 , 30, 537-45	11.2	49
17	Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. <i>Journal of Molecular Biology</i> , 1998 , 282, 125-35	6.5	85
16	Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides. <i>Biological Chemistry</i> , 1997 , 378, 495-502	4.5	8
15	Antibody responses to the hepatitis C virus E2 protein: Relationship to viraemia and prevalence in anti-HCV seronegative subjects. <i>Journal of Medical Virology</i> , 1997 , 51, 1-5	19.7	25
14	Immunization with phage-displayed mimotopes. <i>Methods in Enzymology</i> , 1996 , 267, 109-15	1.7	30
13	Phage-displayed peptides as tools for characterization of human sera. <i>Methods in Enzymology</i> , 1996 , 267, 116-29	1.7	24

12	Selection of biologically active peptides by phage display of random peptide libraries. <i>Current Opinion in Biotechnology</i> , 1996 , 7, 616-21	11.4	104
11	A complex interplay of positive and negative elements is responsible for the different transcriptional activity of liver NF1 variants. <i>Molecular Biology Reports</i> , 1995 , 21, 147-58	2.8	7
10	Identification of biologically active peptides using random libraries displayed on phage. <i>Current Opinion in Biotechnology</i> , 1995 , 6, 73-80	11.4	102
9	Peptide and protein display on the surface of filamentous bacteriophage. <i>Biotechnology Annual Review</i> , 1995 , 1, 149-83		33
8	Epitope discovery using peptide libraries displayed on phage. <i>Trends in Biotechnology</i> , 1994 , 12, 262-7	15.1	124
7	Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. <i>Gene</i> , 1994 , 146, 191-8	3.8	69
6	Monoclonal antibodies that recognise filamentous phage: tools for phage display technology. <i>Gene</i> , 1994 , 148, 7-13	3.8	43
5	A bipartite activation domain is responsible for the activity of transcription factor HNF1/LFB1 in cells of hepatic and nonhepatic origin. <i>DNA and Cell Biology</i> , 1993 , 12, 199-208	3.6	8
4	Transcriptional Control of Gene Expression in Hepatic Cells 1993 , 162-242		2
3	Trans-dominant inhibition of transcription activator LFB1. <i>Nucleic Acids Research</i> , 1992 , 20, 5321-8	20.1	15
2	A myosin-like dimerization helix and an extra-large homeodomain are essential elements of the tripartite DNA binding structure of LFB1. <i>Cell</i> , 1990 , 61, 1225-36	56.2	171
1	The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. <i>Cell</i> , 1989 , 59, 145-57	56.2	489